ZUG, SWITZERLAND -- Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, announced the successful placement of a single-tranche EUR 500 million Eurobond. The bond has a 5-year maturity and carries a fixed-rate annual coupon of 3.375%.

The Eurobond was placed on March 10, 2026, with settlement expected on March 17, 2026, and will be listed on the SIX Swiss Exchange.

Citigroup, ING, J.P. Morgan and RBC Capital Markets jointly led the transaction.

Net proceeds from the transaction will be used to fully repay Galderma’s existing bank term loan issued in connection with the company’s initial public offering in March 2024. The transaction represents the final step in Galderma’s refinancing process, having obtained two investment grade credit ratings.

Galderma is currently rated ‘BBB’ (stable outlook) by Fitch and ‘BBB’ (positive outlook) by S&P Global Ratings (S&P), and the new bond is expected to be rated ‘BBB’ by both agencies.

The successful issuance is leverage-neutral and is not expected to materially affect Galderma’s full-year 2026 guidance for net financial expenses.